Currently, due to development of various pharmacotherapies (SGLT2 inhibitors, DPP4 inhibitors, GLP1 analogs and receptor agonists, insulin sensitizers and long-acting insulin analogs) case-tailored T2DM management is increasingly successful, leading to both a decrease in hyperglycemia and T2DM comorbidities6,7. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.